Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Author:

Moreau PhilippeORCID,Chari Ajai,Oriol AlbertORCID,Martinez-Lopez Joaquin,Haenel Mathias,Touzeau CyrilleORCID,Ailawadhi SikanderORCID,Besemer Britta,de la Rubia Comos JavierORCID,Encinas CristinaORCID,Mateos Maria-VictoriaORCID,Salwender HansORCID,Rodriguez-Otero PaulaORCID,Hulin CyrilleORCID,Karlin Lionel,Sureda Balari Anna,Bargay Joan,Benboubker Lotfi,Rosiñol LauraORCID,Tarantolo Stefano,Terebelo Howard,Yang Shiyi,Wang Jianping,Nnane Ivo,Qi Ming,Kosh Michele,Delioukina Maria,Goldschmidt HartmutORCID

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Reference14 articles.

1. DARZALEX® (daratumumab) injection, for intravenous use [package insert]. Janssen Biotech, Inc. 2022.

2. European Medicines Agency. DARZALEX 20 mg/mL concentrate for solution for infusion [summary of product characteristics]. https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf. Accessed Oct 2022.

3. DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use [package insert]. Janssen Biotech, Inc. 2022.

4. Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801–12.

5. Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20:509–18.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3